Compare Illumina, Inc. (ILMN) vs Wix.Com Ltd (WIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs Wix.Com Ltd — how do they compare? Illumina, Inc. trades at $191.6 (market cap $27.94B), while Wix.Com Ltd trades at $51.63 (market cap $2.23B). The key difference: Illumina, Inc. is far larger — about 12.5× Wix.Com Ltd's market cap, and Illumina, Inc. is trading nearer its 52-week high, Wix.Com Ltd nearer its low. Which is the better fit depends on your goals.
| ILMN | WIX | |
|---|---|---|
Market Cap | $27.94B | $2.23B |
Sector | Health | Technology |
52-Week High | $194.33 | $184.24 |
52-Week Low | $91.00 | $40.43 |
Enterprise Value | $29.33B | $1.80B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $185.36, down 0.69% on the day, with a bullish technical signal from moving averages. The stock shows strong profitability with a 19.42% net income margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights expansion of the Billion Cell Atlas program and upcoming Q2 2026 earnings on July 30.
Outlook remains positive with 51% analyst buy ratings, though the current price exceeds the $178 consensus target. Key risks include competitive pressure from Roche's new sequencer and China market weakness. Earnings growth and cost control initiatives support upside potential, but valuation multiples suggest limited near-term appreciation.
Wix trades at $53.34, up 3.67% on the day, with a bearish technical signal and mixed fundamentals. Revenue grew to $1.99B in 2025, but net income fell to $50.65M with a negative margin of -1.97%. The stock faces headwinds from recent earnings misses and legal investigations, yet maintains strong analyst support with a consensus price target of $83.07.
The outlook is cautious due to high valuation multiples and operational risks, but long-term growth potential exists if Wix can leverage AI tools and partnerships to improve profitability. Key risks include competitive pressure and ongoing legal scrutiny, while institutional sentiment remains predominantly bullish.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About Wix.Com Ltd
Wix.com Ltd is a cloud-based development platform provider for millions of registered users worldwide. The company is engaged in web development and management that provides an easy-to-use powerful cloud-based platform of products through a freemium model. Its core products consist of three web editors: the Wix Editor, intended for users with basic technological skills, Wix ADI, intended for novice users and Corvid, intended for more tech-savvy users. The company's web development technology is built based on HTML5 and offers HTML5 compatible capabilities, web design and layout tools, domain hosting, and other marketing and workflow management applications and services. The geographic segments include North America, Europe, Latin America, Asia and others.
Read more on WIX →
